Jabil Enhances Pharmaceutical Capacity with Pii Acquisition
Deal News | Feb 04, 2025 | Signet Healthcare Partners LLC
Jabil Inc. announced the acquisition of Pharmaceutics International, Inc. (Pii), expanding its capabilities in the pharmaceutical manufacturing sector. This acquisition is aimed at enhancing Jabil's offerings in pharmaceutical solutions, particularly in the clinical and commercial drug manufacturing space. The merger includes Pii's vast expertise in aseptic filling and oral solid dose manufacturing, complementing Jabil's existing expertise in auto-injectors and other drug delivery systems. Executives from both firms highlight the synergies expected from the acquisition, which benefits from Jabil's robust global infrastructure and technological capabilities. With this acquisition, Jabil aims to meet the increasing demands of healthcare innovation by offering comprehensive end-to-end solutions for pharmaceutical clients.
Sectors
- Pharmaceutical Manufacturing
- Contract Development and Manufacturing Organization (CDMO)
- Healthcare Solutions
Geography
- United States – Both Jabil and Pharmaceutics International, Inc. operate primarily in the U.S., with Pii located in Maryland and Jabil headquartered in Florida.
Industry
- Pharmaceutical Manufacturing – Involves the large-scale production of pharmaceutical products and drugs, which aligns with Jabil and Pii's operations in drug production and development.
- Contract Development and Manufacturing Organization (CDMO) – Provides outsourcing services for drug development and manufacturing, relevant due to Pii's position as a CDMO and Jabil's entry into this market.
- Healthcare Solutions – Encompasses the products and services aimed at improving healthcare delivery, relevant as Jabil enhances its healthcare solutions portfolio with this acquisition.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Jabil Inc. | Bidding Company/Buyer | Company | A global leader in engineering, manufacturing, and supply chain solutions, expanding its healthcare and pharmaceutical solutions. |
| Pharmaceutics International, Inc. (Pii) | Target Company | Company | A CDMO specializing in aseptic filling, lyophilization, and oral solid dose manufacturing, providing drug development services. |
| Signet Healthcare Partners LLC | Selling Company | Company | A healthcare investment firm involved in the sale of Pharmaceutics International, Inc. |
| Athyrium Capital Management | Shareholder | Company | Private equity firm and shareholder of Pii involved in the transaction. |
| Hildred Capital | Shareholder | Company | Investment firm and shareholder of Pii participating in the sale. |
| Pharmascience Inc. | Shareholder | Company | Pharmaceutical company and shareholder of Pii contributing to the transaction. |